Paper Details

  1. Home
  2. Paper Details

The skeletal effects of the tyrosine kinase inhibitor nilotinib.

Author: AatiOpetaia, BrowettPeter, CallonKaren, CornishJillian, GambleGreg, GreyAndrew, HorneAnne, LinJian-Ming, NaotDorit, O'SullivanSusannah, PorteousFran, TongPak Cheung, WatsonMaureen

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study assessed the effects of nilotinib, a tyrosine kinase inhibitor, on bone cells in vitro and on bone metabolism in patients with chronic myeloid leukemia (CML). Nilotinib potently inhibited osteoblast proliferation and osteoclastogenesis in vitro. In 10 patients receiving nilotinib, levels of bone turnover markers were in the low-normal range and bone density tended to be higher than age and gender-matched normal values.
Paper Details　
Original Abstract of the Article :
Nilotinib is a tyrosine kinase inhibitor (TKI) developed to manage imatinib-resistance in patients with chronic myeloid leukemia (CML). It inhibits similar molecular targets to imatinib, but is a significantly more potent inhibitor of Bcr-Abl. Nilotinib exhibits off-target effects in other tissues, ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.bone.2011.04.014

データ提供：米国国立医学図書館（NLM）

Nilotinib and Bone Metabolism: Navigating the Desert of Side Effects

Imagine a vast desert landscape, where the effects of medication can be unpredictable and sometimes harmful. This research investigates the potential effects of nilotinib, a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML), on bone metabolism. The researchers carefully examined the impact of nilotinib on bone cells in laboratory settings, seeking to understand the potential side effects of this important medication.

A Journey Through the Desert of Bone Metabolism: Navigating the Effects of Nilotinib

The research revealed that nilotinib exhibited a complex influence on bone cells, inhibiting osteoblast proliferation and differentiation while also suppressing osteoclastogenesis. It's like encountering a hidden oasis in the desert, but realizing that its waters might not be as pure as they initially appear. The researchers observed that while nilotinib could have a positive effect on bone density, it could also lead to hypophosphatemia, a condition that can affect bone health. This highlights the need for careful monitoring and management of bone metabolism in patients receiving nilotinib therapy.

Finding a Balance: Understanding the Potential Risks and Benefits

This research underscores the importance of understanding the potential side effects of medications and developing strategies to mitigate these risks. It's like navigating a desert landscape, where knowledge and caution are essential for survival. The researchers emphasize the need for further studies to assess the long-term effects of nilotinib on bone health, striving to find a balance between the benefits of this medication and the potential risks to bone metabolism.

Dr.Camel's Conclusion

This research provides valuable insights into the potential effects of nilotinib on bone metabolism, reminding us that even with groundbreaking medications, we must carefully navigate the desert of side effects. The researchers encourage continued exploration of this important medication, seeking to optimize its use and ensure the long-term health and well-being of patients receiving this treatment.

Date :
  1. Date Completed 2011-12-14
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

21550432

DOI: Digital Object Identifier

10.1016/j.bone.2011.04.014

Related Literature

Article Analysis
・Effects of nilotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.